La vendita allo scoperto per enVVeno Medical dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di enVVeno Medical. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

enVVeno Medical (NASDAQ:NVNO) Azioni, Report sulle vendite allo scoperto

enVVeno Medical

enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).

enVVeno Medical Corporation - Common Stock

enVVeno Medical Corp

WIIM

SAVA

Cassava Sciences  shares are trading lower after the company announced Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease in the ReThink-ALZ Phase 3 study.

Biotech

News

General

ALUR

Allurion Launches AllurionMeds In The U.S., Combining AI-Driven GLP-1 Weight Loss Program With Coach Iris For Long-Term Maintenance, Expanding Reach To All 50 States And Advancing Mission To Combat Obesity

BBIO

BridgeBio Pharma shares are trading higher after the company announced that the FDA approved Attruby to treat adults with ATTR-CM. Also, HC Wainwright maintained a Buy rating on the stock and raised its price target from $43 to $49.

<p>Small Cap Consumer Research  analyst Eric Beder   reiterates Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) with a Buy and maintains $29 price target.</p>


Price Target

Reiteration

Analyst Ratings

Small Cap Consumer Research Reiterates Buy on Guess, Maintains $29 Price Target

<p>Canaccord Genuity  analyst Joseph Vafi   maintains MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) with a Buy and raises the price target from $300 to $510.</p>


MSTR

Canaccord Genuity Maintains Buy on MicroStrategy, Raises Price Target to $510

Financing

VSTE

Vast Signs Updated Funding Agreement To Access Up To $30M Of Its $65M Grant From The Australian Renewable Energy Agency

<p><i>Brightcove Stockholders to Receive $4.45 Per Share in Cash</i></p>
<p><i>Bending Spoons enters the enterprise SaaS market and will draw on its technology expertise to further strengthen Brightcove and bring its cutting-edge platform to new heights</i></p>
<p><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect-us.mimecast.com%2Fs%2FTT0ACXD7rNIDpARJTkWLIt%3Fdomain%3Dbrightcove.com&amp;esheet=54157477&amp;newsitemid=20241124779994&amp;lan=en-US&amp;anchor=Brightcove+Inc.&amp;index=1&amp;md5=4089cc9217606a25bce452fc6f364d4e">Brightcove Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCOV#NASDAQ">BCOV</a>), the world's most trusted streaming technology company, today announced that it has entered into a definitive agreement to be acquired by Bending Spoons, in an all-cash transaction valued at approximately $233 million. Under the terms of the agreement, Brightcove shareholders will receive $4.45 per share in cash for each share of Brightcove common stock that they own. The per share purchase price represents a 90% premium over Brightcove's 60-day volume weighted average share price as of the close on November 22, 2024.</p>


BCOV

Brightcove Enters Into Definitive Agreement To Be Acquired By Bending Spoons For $233M; Brightcove Stockholders To Receive $4.45 Per Share In Cash

Tsetsaut Skii km Lax Ha Nation Files For Judicial Review Of B.C.'s Substantial Start Determination For Seabridge Gold's KSM Mine; Despite Seabridge's Plan To Locate The Mine's Immense Toxic Waste Facilities On The Nation's Exclusive Traditional Territory, The Province Has Not Engaged In The Meaningful Consultation Required By The Canadian Constitution

TOYO

Toyo Co. To Acquire Texas-Based Solar Module Manufacturing Facility With Initial 2.5 GW Capacity, Plans Expansion To 6.5 GW By 2029 To Meet U.S. Demand For American-Made Solar Panels; Financial Terms Not Disclosed

<p>B of A Securities  analyst Alec Stranahan   downgrades Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) from Buy to Neutral and lowers the price target from $24 to $6.</p>


Downgrades

CATX

B of A Securities Downgrades Perspective Therapeutics to Neutral, Lowers Price Target to $6

<p>Telsey Advisory Group  analyst Dana Telsey   maintains Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) with a Market Perform and maintains $8 price target.</p>


CURV

Telsey Advisory Group Maintains Market Perform on Torrid Holdings, Maintains $8 Price Target

<p><i>Upon Completion of the Investment, this facility will have a 50MW capacity for Bitcoin Mining</i></p>
<p>ONTARIO, Calif., Nov. 25, 2024 /PRNewswire/ --&nbsp;Nature's Miracle Holding Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) ("Nature's Miracle" or the "Company"), announced today it has formed NM Data Inc., a Nevada Corporation and 100% subsidiary,&nbsp;to develop and acquire Bitcoin mining facilities. NM Data has&nbsp;signed an agreement to invest up to $3 million in Future Tech Incorporated ("Future Tech"), an Ohio-based company, to develop and build up to 50MW of Bitcoin mining and data center hosting facilities at Stryker, Ohio. With the $3 million investment, NM Data, Inc will own 51% of Future Tech, Inc.</p>
<p>The initial investment is $200,000 and the additional $2,800,000 is to be paid within 12 months of the initial closing. The closing of the investment of the $3 million is subject to Future Tech's executing an Electricity Sales and Purchase Agreement with a certain supplier set forth in the agreement and Future Tech entering into a ten-year lease option to purchase indoor space as set forth in the agreement. &nbsp;NM Data will invest additional capital to complete the 50MW bitcoin mining facility.</p>


Contracts

NMHI

Nature's Miracle Holding Launches NM Data Inc. And Announces $3M Investment In Future Tech, Inc. To Develop A 50MW Bitcoin Mining Facility In Ohio

<p>Small Cap Consumer Research  analyst Eric Beder   reiterates Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) with a Buy and maintains $6 price target.</p>


Small Cap Consumer Research Reiterates Buy on Vera Bradley, Maintains $6 Price Target

<p>Intrusion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>), a leader in cyberattack prevention solutions, today announced the launch of the Intrusion Shield Command Hub, a centralized hub that allows MSPs and network administrators a way to view, manage, and report on an entire fleet of Shield products, including Endpoint, OnPremise, and Cloud. The Command Hub's latest feature is an AI-driven insights engine that analyzes vast quantities of network activity and gives administrators a prioritized list of actionable items based on its analysis.</p>
<p>The Command Hub provides key insights into network health, traffic patterns, and potential threats, making it easier to stay ahead of risks across an organization's infrastructure. Whether you are a seasoned security expert or someone with limited technical experience, the Command Hub's intuitive design makes it easy for any level of expertise to navigate and leverage its powerful features, making it an ideal tool for both day-to-day operations and advanced threat-hunting. The Command Hub offers a high level of visibility and control over network activities, ensuring administrators can monitor critical security metrics across multiple devices from a single interface.</p>
<p>The shining star of the Command Hub is its AI Insights engine. This feature provides meaningful, data-driven insights by analyzing vast quantities of network activity. It identifies potential risks, unusual behavior, and areas that require attention, offering actionable steps that administrators can take to improve their network's security posture. The AI engine also offers multiple layers of abstraction, allowing visibility from individual device activity all the way up to customer-wide summaries, making it that much more effective for fleet management. In addition, it provides visual representations of the data, making it easier to interpret and act upon critical security insights.</p>


INTZ

Intrusion Launches Of The Intrusion Shield Command Hub, A Centralized Hub That Allows MSPs And Network Administrators A Way To View, Manage, And Report On An Entire Fleet Of Shield Products, Including Endpoint, OnPremise, And Cloud

<p>B of A Securities  analyst Mariana Perez   maintains Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) with a Buy and raises the price target from $55 to $75.</p>


PLTR

B of A Securities Maintains Buy on Palantir Technologies, Raises Price Target to $75

<p>Providing a diverse range of perspectives from bullish to bearish, 18 analysts have published ratings on Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) in the last three months.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">11</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $96.06, a high estimate of $125.00, and a low estimate of $75.00. This current average has decreased by 1.21% from the previous average price target of $97.24. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732539707_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Five Below. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$95.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$88.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Melanie Nunez</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$75.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$104.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>David Bellinger</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>David Bellinger</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Jeremy Hamblin</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Melanie Nunez</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$98.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Karen Short</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Hold</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$95.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$102.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Bradley Thomas</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$106.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$106.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$87.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$89.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$95.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Jeremy Hamblin</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Buy</td>
<td>$102.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Melanie Nunez</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$87.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Five Below. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Five Below compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Five Below's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Five Below's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FIVE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Five Below analyst ratings.</strong></a></p>
<h2>All You Need to Know About Five Below</h2>
<p>Five Below Inc is a specialty value retailer offering merchandise targeted at the tween and teen demographic. The Company's edited assortment of products includes select brands and licensed merchandise.</p>
<h3>Five Below's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Five Below showcased positive performance, achieving a revenue growth rate of <strong>9.37%</strong> as of 31 July, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Five Below's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.98%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Five Below's ROE excels beyond industry benchmarks, reaching <strong>2.07%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Five Below's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.83%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Five Below's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>1.18</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FIVE

A Closer Look at 18 Analyst Recommendations For Five Below

<p>Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">11</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Rhythm Pharmaceuticals and provided 12-month price targets. The average target is $66.15, accompanied by a high estimate of $80.00 and a low estimate of $52.00. This upward trend is evident, with the current average reflecting a 4.83% increase from the previous average price target of $63.10.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732539688_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The perception of Rhythm Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$69.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$69.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Phil Nadeau</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$64.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$64.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Rhythm Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Rhythm Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Rhythm Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Rhythm Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RYTM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Rhythm Pharmaceuticals analyst ratings.</strong></a></p>
<h2>About Rhythm Pharmaceuticals</h2>
<p>Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.</p>
<h3>Breaking Down Rhythm Pharmaceuticals's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Rhythm Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>47.76%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Rhythm Pharmaceuticals's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-131.25%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-172.64%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Rhythm Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-11.71%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.36</strong>, Rhythm Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


RYTM

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 13 Analysts

<p>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) will report on Q3 2024.</p>


Earnings

NCNA

NuCana Q3 2024 GAAP EPS Of £(0.07) Versus £(0.13) YoY, Cash And Cash Equivalents Of £11.4M Expected To Provide Cash Runway Into Q2 2025

<p>14 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of $205.00, and a low estimate of $80.00. Experiencing a 5.56% decline, the current average is now lower than the previous average price target of $178.73. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732539677_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Sarepta Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Sell</td>
<td>$80.00</td>
<td>-</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$193.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$167.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Gavin Clark-Gartner</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$182.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Andrew Tsai</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$182.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$152.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sarepta Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Sarepta Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Sarepta Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Sarepta Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SRPT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Sarepta Therapeutics analyst ratings.</strong></a></p>
<h2>Discovering Sarepta Therapeutics: A Closer Look</h2>
<p>Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.</p>
<h3>Understanding the Numbers: Sarepta Therapeutics's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Sarepta Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>40.79%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Sarepta Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of <strong>7.19%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>2.93%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Sarepta Therapeutics's ROA excels beyond industry benchmarks, reaching <strong>0.96%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Sarepta Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>1.14</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SRPT

Analyst Expectations For Sarepta Therapeutics's Future

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   reiterates Assertio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASRT#NASDAQ">ASRT</a>) with a Buy and maintains $4 price target.</p>


ASRT

HC Wainwright & Co. Reiterates Buy on Assertio Holdings, Maintains $4 Price Target

enVVeno Medical reports Q1 results

enVVeno Medical reports Q2 results

enVVeno Medical offers to sell common stock

enVVeno Medical stock falls after it prices $15M securities offering

Catalyst Watch: Tesla's Robotaxi reveal, AI events for Nvidia, AMD, and HP Enterprise

Catalyst Watch: Netflix earnings, Lenovo tech event, Paris Motor Show, and eyes on oil

enVVeno announced the start to its six-month pre-clinical GLP study for enVVe, its transcatheter-delivered replacement venous valve. The first wave...

enVVeno Medical initiates six-month pre-clinical GLP study of enVVe

"We are working diligently to collect and analyze the definitive data that we need to complete our PMA application seeking approval from the FDA fo...

enVVeno Medical reports Q3 EPS (35c) vs. (45c) last year

The Company ended the quarter with $48.4 million in cash and investments. On September 30, 2024, the Company closed an offering raising approximate...

enVVeno Medical expects capital to fund company through several milestones

enVVeno Medical rises on submission of the venovalve PMA application for FDA approval

ABNB

ACCD

ADBE

AGYS

ALKS

ALLY

AMZN

APLD

BIDU

BLNK

BYDDF

BYND

CAPR

CELH

COST

CTRI

CYTK

EVRI

FAST

FLUT

GDRZF

GOOG

GSAT

GWRE

HELE

IBTA

ILMN

INTC

LNVGY

MIRM

MSFT

MTEN

MYGN

NAPA

NFLX

NRBO

NVDA

NVNO

OCGN

OKTA

QCOM

SCHW

SERV

SFHG

SITC

SMAR

SRRK

TSLA

UBER

ULTA

USGO

VANI

VLKAF

VRSSF

VSTO

VTNR

ZLDPF

Events

Press Releases

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update

enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)

Management

enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing

enVVeno Medical Corporation Announces Proposed Public Offering

enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering

enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)

enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

Adagio Medical Holdings, Inc - Common Stock

Adagio Medical Holdings

Apyx Medical

Accelerate Diagnostics, Inc. - Common Stock

Accelerate Diagnostics

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

HeartBeam

BioSig Technologies

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical

CytoSorbents

DIH Holding US, Inc. - Class A Common Stock

DIH Holding US

Daxor

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

enVVeno Medical

Vendite allo scoperto

enVVeno Medical (NASDAQ:NVNO) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO